Works matching DE "MARAVIROC (Drug)"

Results: 187

Pharmacologic Drug Detection and Self-Reported Adherence in the HPTN069/ACTG5305 Phase II PrEP Trial.

Published in:

AIDS & Behavior, 2024, v. 28, n. 11, p. 3710, doi. 10.1007/s10461-024-04451-7

By:

Cooper, Stanley E.;
Zhang, Shuaiqi;
Haines, Daniel;
Mayer, Kenneth H.;
Amico, K. Rivet;
Landovitz, Raphael J.;
Hendrix, Craig W.;
Marzinke, Mark A.;
Chege, Wairimu;
McCauley, Marybeth;
Gulick, Roy M.

Publication type:

Article

Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305).

Published in:

AIDS & Behavior, 2022, v. 26, n. 12, p. 4107, doi. 10.1007/s10461-022-03736-z

By:

Mayer, Kenneth H.;
Yuhas, Krista;
Amico, K. Rivet;
Wilkin, Timothy;
Landovitz, Raphael J.;
Richardson, Paul;
Marzinke, Mark A.;
Hendrix, Craig. W;
Eshleman, Susan H.;
Cottle, Leslie M.;
Marcus, Cheryl;
Chege, Wairimu;
Rinehart, Alex R.;
Rooney, James F.;
Andrew, Philip;
Salata, Robert A.;
Magnus, Manya;
Farley, Jason E.;
Liu, Albert Y.;
Frank, Ian

Publication type:

Article

Interactions between Alcohol and the HIV Entry Inhibitor Maraviroc.

Published in:

Journal of the International Association of Providers of AIDS Care, 2013, v. 12, n. 6, p. 375, doi. 10.1177/2325957413495567

By:

Gruber, Valerie A.;
Rainey, Petrie M.;
Lum, Paula J.;
Beatty, George W.;
Aweeka, Francesca T.;
McCance-Katz, Elinore F.

Publication type:

Article

The effect of maraviroc on the pharmacokinetics of digoxin in healthy volunteers.

Published in:

Clinical Pharmacology in Drug Development, 2014, v. 3, n. 3, p. 202, doi. 10.1002/cpdd.91

By:

Vourvahis, Manoli;
Fang, Juanzhi;
Choo, Heng Wee;
Heera, Jayvant

Publication type:

Article

Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug R. E. Kast Translational medicine.

Published in:

Journal of Clinical Pharmacy & Therapeutics, 2010, v. 35, n. 6, p. 657, doi. 10.1111/j.1365-2710.2009.01148.x

By:

Kast, R. E.

Publication type:

Article

In Vitro Immunological Effects of Blocking CCR5 on T Cells.

Published in:

Inflammation, 2015, v. 38, n. 2, p. 902, doi. 10.1007/s10753-014-0052-6

By:

Yuan, Jing;
Ren, Han-yun;
Shi, Yong-jin;
Liu, Wei

Publication type:

Article

V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1-infected, treatment-experienced persons receiving optimized background regimens.

Published in:

Antiviral Chemistry & Chemotherapy, 2021, p. 1, doi. 10.1177/20402066211030380

By:

Lewis, M. E.;
Simpson, P.;
Mori, J.;
Jubb, B.;
Sullivan, J.;
McFadyen, L.;
van der Ryst, E.;
Craig, C.;
Robertson, D. L.;
Westby, M.

Publication type:

Article

Highly prevalent Russian HIV-1 V3-loop sequence variants are susceptible to maraviroc.

Published in:

Antiviral Chemistry & Chemotherapy, 2021, p. 1, doi. 10.1177/20402066211025156

By:

Lewis, M. E.;
Jubb, B.;
Simpson, P.;
Lopatukhin, A.;
Kireev, D.;
Bobkova, M.;
Craig, C.;
van der Ryst, E.;
Westby, M.;
Butler, S. L.

Publication type:

Article

Long-term Maraviroc Therapy and Limited Side Effects in an HIV-1 Experienced Patient: Six Years of Antiretroviral Observation.

Published in:

2014

By:

Cirioni, O.;
Weimer, L. E.;
Fragola, V.;
Giacometti, A.;
Sozio, F.

Publication type:

Case Study

Mutations in variable domains of the HIV-1 envelope gene can have a significant impact on maraviroc and vicriviroc resistance.

Published in:

AIDS Research & Therapy, 2013, v. 10, p. 15, doi. 10.1186/1742-6405-10-15

By:

Asin-Milan, Odalis;
Chamberland, Annie;
Yi Wei;
Haidara, Alpha;
Sylla, Mohamed;
Tremblay, Cécile L.

Publication type:

Article

HIV Medications: An Update and Review of Metabolic Complications.

Published in:

2012

By:

Hester, E. Kelly

Publication type:

Journal Article

Network meta‐analysis of post‐exposure prophylaxis randomized clinical trials.

Published in:

HIV Medicine, 2021, v. 22, n. 3, p. 218, doi. 10.1111/hiv.12964

By:

Fernández, I;
Lazzari, E.;
Inciarte, A.;
Diaz‐Brito, V.;
Milinkovic, A.;
Arenas‐Pinto, A.;
Etcheverrry, F.;
García, F.;
Leal, L;
Fernandez, E;
Gonzalez, E;
Lucero, C;
Leon, A;
Garcıa, F;
Manzardo, C;
Nicolas, D;
Bodro, M;
del Rıo, A;
Cardozo, C;
Cervera, C

Publication type:

Article

Week 96 results of the randomized, multicentre Maraviroc Switch ( MARCH) study.

Published in:

HIV Medicine, 2018, v. 19, n. 1, p. 65, doi. 10.1111/hiv.12532

By:

Pett, S. L.;
Amin, J.;
Horban, A.;
Andrade‐Villanueva, J.;
Losso, M.;
Porteiro, N.;
Madero, J. S.;
Belloso, W.;
Tu, E.;
Silk, D.;
Kelleher, A.;
Harrigan, R.;
Clark, A.;
Sugiura, W.;
Wolff, M.;
Gill, J.;
Gatell, J.;
Clarke, A.;
Ruxrungtham, K.;
Prazuck, T.

Publication type:

Article

Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study.

Published in:

HIV Medicine, 2017, v. 18, n. 7, p. 482, doi. 10.1111/hiv.12479

By:

Poveda, E;
Hernández‐Quero, J;
Pérez‐Elías, MJ;
Ribas, MA;
Martínez‐Madrid, OJ;
Flores, J;
Navarro, J;
Gutiérrez, F;
García‐Deltoro, M;
Imaz, A;
Ocampo, A;
Artero, A;
Blanco, F;
Bernal, E;
Pasquau, J;
Mínguez‐Gallego, C;
Pérez, N;
Aiestaran, A;
García, F;
Paredes, R

Publication type:

Article

Off-licence use of once-daily maraviroc in children and adolescents with perinatally acquired HIV-1 infection.

Published in:

HIV Medicine, 2017, v. 18, n. 4, p. 311, doi. 10.1111/hiv.12467

By:

Fraser‐Taliente, T;
Mackie, NE;
Kaye, S;
Nyirenda, M;
Foster, C

Publication type:

Article

Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.

Published in:

HIV Medicine, 2015, v. 16, n. 6, p. 388, doi. 10.1111/hiv.12243

By:

Tiraboschi, JM;
Muñoz‐Moreno, JA;
Puertas, MC;
Alonso‐Villaverde, C;
Prats, A;
Ferrer, E;
Rozas, N;
Maso, M;
Ouchi, D;
Martinez‐Picado, J;
Podzamczer, D

Publication type:

Article

Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting.

Published in:

HIV Medicine, 2014, v. 15, n. 7, p. 417, doi. 10.1111/hiv.12129

By:

Macías, J;
Recio, E;
Márquez, M;
García, C;
Jiménez, P;
Merino, D;
Muñoz, L;
Pasquau, J;
Ojeda, G;
Bancalero, P;
Chueca, N;
Pineda, JA

Publication type:

Article

Maraviroc - a CCR5 antagonist for the treatment of HIV-1 infection.

Published in:

2015

By:

Van Der Ryst, Elna

Publication type:

Opinion

Two-Drug Treatment Approaches in HIV: Finally Getting Somewhere?

Published in:

Drugs, 2016, v. 76, n. 5, p. 523, doi. 10.1007/s40265-016-0553-8

By:

Kelly, Sean;
Nyaku, Amesika;
Taiwo, Babafemi

Publication type:

Article

Serious neuropsychiatric adverse effects related to interaction between itraconazole and darunavir/ritonavir in an HIV-infected patient with cerebral histoplasmosis.

Published in:

2018

By:

Meur, Lucie Le;
Tantet, Claire;
Lê, Minh Patrick;
Desselas, Emilie;
Bonnal, Christine;
Lillo-Le-Louet, Agnès;
Sonneville, Romain;
Massias, Laurent;
Giraud, Julie;
Descamps, Diane;
Le Meur, Lucie;
Yazdanpanah, Yazdan;
Lariven, Sylvie;
Peytavin, Gilles

Publication type:

journal article

Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial.

Published in:

2018

By:

Pressiat, Claire;
Hirt, Déborah;
Treluyer, Jean-Marc;
Zheng, Yi;
Morlat, Philippe;
Naqvi, Alice;
Tran, Laurent;
Viard, Jean-Paul;
Avettand-Fenoel, Véronique;
Rouzioux, Christine;
Meyer, Laurence;
Cheret, Antoine;
OPTIPRIM Study Group

Publication type:

journal article

INFECTIOUS DISEASES.

Published in:

2014

By:

Rawlins, Matthew

Publication type:

Abstract

Administration of crushed maraviroc via percutaneous gastrostomy tube in a patient with human immunodeficiency virus and progressive multifocal leukoencephalopathy.

Published in:

2019

By:

Fulco, Patricia Pecora;
Gatesman, Travis L

Publication type:

Case Study

NEW DRUGS AND DOSAGE FORMS.

Published in:: 2016
Publication type:: Product Review

Management of HIV-2 resistance to antiretroviral therapy in a HIV-1/HIV-2/HBV co-infected patient.

Published in:

AIDS Research & Therapy, 2021, v. 18, n. 1, p. 1, doi. 10.1186/s12981-021-00394-4

By:

Cardoso, Margarida;
Vasconcelos, Joana;
Baptista, Teresa;
Diogo, Isabel;
Gonçalves, Fátima;
Mansinho, Kamal;
Gomes, Perpétua

Publication type:

Article

HIV-1 subtype C predicted co-receptor tropism in Africa: an individual sequence level meta-analysis.

Published in:

AIDS Research & Therapy, 2020, v. 17, n. 1, p. 1, doi. 10.1186/s12981-020-0263-x

By:

Matume, Nontokozo D.;
Tebit, Denis M.;
Bessong, Pascal O.

Publication type:

Article

Darunavir-based dual therapy of treatment-experienced HIV-infected patients: analysis from a national multicenter database.

Published in:

Infection, 2015, v. 43, n. 3, p. 339, doi. 10.1007/s15010-015-0764-z

By:

Sterrantino, Gaetana;
Zaccarelli, Mauro;
Biagio, Antonio;
Biondi, Maria;
Antinori, Andrea;
Penco, Giovanni

Publication type:

Article

Abstracts ICAR 2010.

Published in:: Infection, 2010, v. 38, p. 1, doi. 10.1007/s15010-010-1001-4
Publication type:: Article

Maraviroc in Antiretroviral-Naïve HIV-1 Patients.

Published in:

Infectious Diseases: Research & Treatment, 2012, n. 5, p. 1, doi. 10.4137/IDRT.S7597

By:

Ghebremedhin, Beniam

Publication type:

Article

Antiretroviral agents: Focus on Maraviroc for the Treatment of HIV-1-Infected Adults.

Published in:

Clinical Medicine Insights: Therapeutics, 2010, n. 2, p. 697, doi. 10.4137/CMT.S5420

By:

Pett, S. L.;
Emery, S.;
Kelleher, A. D.;
Cooper, D. A.

Publication type:

Article

Not Recommended, But Done: Breastfeeding with HIV in Germany.

Published in:

AIDS Patient Care & STDs, 2021, v. 35, n. 2, p. 33, doi. 10.1089/apc.2020.0223

By:

Haberl, Lila;
Audebert, Franz;
Feiterna-Sperling, Cornelia;
Gillor, Daniel;
Jakubowski, Peter;
Jonsson-Oldenbüttel, Celia;
Khaykin, Pavel;
Kiener, Rita;
Reitter, Anke;
Rieke, Ansgar;
Rodríguez, Elena;
Rößler, Steve;
Rump, Jörg-Andres;
Schüttfort, Gundolf;
Stephan, Christoph;
Ulmer, Albrecht;
von Braun, Amrei;
von Weizsäcker, Katharina;
Haberl, Annette

Publication type:

Article

Oral CCR5 Inhibitors to Prevent HIV Transmission: The New 'Morning-Before Pill'?

Published in:

Journal of Investigative Dermatology, 2013, v. 133, n. 12, p. 2662, doi. 10.1038/jid.2013.383

By:

Piguet, Vincent

Publication type:

Article

Maraviroc decreases CCL8-mediated migration of CCR5 regulatory T cells and reduces metastatic tumor growth in the lungs.

Published in:

OncoImmunology, 2016, v. 5, n. 6, p. 1, doi. 10.1080/2162402X.2016.1150398

By:

Halvorsen, E. C.;
Hamilton, M. J.;
Young, A.;
Wadsworth, B. J.;
LePard, N. E.;
Lee, H. N.;
Firmino, N.;
Collier, J. L.;
Bennewith, K. L.

Publication type:

Article

Maraviroc Failed to Control Progressive Multifocal Leukoencephalopathy-Associated IRIS in a Patient with Advanced HIV Infection.

Published in:

2014

By:

Rodríguez, Mónica;
Silva-Sánchez, Fernando Antonio;
Luna-Rivero, César;
Vega-Barrientos, Ricardo;
la Barrera, Claudia Alvarado-de;
Reyes-Terán, Gustavo

Publication type:

Case Study

Effectiveness, safety, durability and immune recovery in a retrospective, multicentre, observational cohort of ART-experienced, HIV-1-infected patients receiving maraviroc.

Published in:

2017

By:

Dentone, C.;
Sterrantino, G.;
Signori, A.;
Cenderello, G.;
Guerra, M.;
De Leo, P.;
Bartolacci, V.;
Mantia, E.;
Orofino, G.;
Giacomini, M.;
Bruzzone, B.;
Francisci, D.;
Di Biagio, A.;
MARHIV Study Group

Publication type:

journal article

The utility of genotypic tropism testing in clinical practice.

Published in:

International Journal of STD & AIDS, 2015, v. 26, n. 8, p. 593, doi. 10.1177/0956462414546917

By:

Wyatt, H;
Herman, OM;
Macartney, M;
Conibear, T;
Garcia-Diaz, A;
Booth, C;
McCormick, A;
Smith, C;
Johnson, MA;
Irish, D;
Webster, DP

Publication type:

Article

Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors.

Published in:

International Journal of STD & AIDS, 2012, v. 23, n. 7, p. 459, doi. 10.1258/ijsa.2012.011391

By:

Bucciardini, R.;
D'Ettorre, G.;
Baroncelli, S.;
Ceccarelli, G.;
Parruti, G.;
Weimer, L. E.;
Fragola, V.;
Galluzzo, C. M.;
Pirillo, M. F.;
Lucattini, S.;
Bellagamba, R.;
Francisci, D.;
Ladisa, N.;
Antoni, A. Degli;
Guaraldi, G.;
Manconi, P. E.;
Vullo, V.;
Preziosi, R.;
Cirioni, O.;
Verucchi, G.

Publication type:

Article

Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial.

Published in:

PLoS ONE, 2017, v. 12, n. 11, p. 1, doi. 10.1371/journal.pone.0187393

By:

Rossetti, Barbara;
Gagliardini, Roberta;
Meini, Genny;
Sterrantino, Gaetana;
Colangeli, Vincenzo;
Re, Maria Carla;
Latini, Alessandra;
Colafigli, Manuela;
Vignale, Francesca;
Rusconi, Stefano;
Micheli, Valeria;
Di Biagio, Antonio;
Orofino, Giancarlo;
Ghisetti, Valeria;
Fantauzzi, Alessandra;
Vullo, Vincenzo;
Grima, Pierfrancesco;
Francisci, Daniela;
Mastroianni, Claudio;
Antinori, Andrea

Publication type:

Article

Differences in the variability of cerebral proton magnetic resonance spectroscopy (<sup>1</sup>H-MRS) measurements within three HIV-infected cohorts.

Published in:

Neuroradiology Journal, 2015, v. 28, n. 6, p. 545, doi. 10.1177/1971400915609867

By:

Vigneswaran, Shivanee;
Rojas, Jaime H. Vera;
Garvey, Lucy;
Taylor-Robinson, Simon;
Winston, Alan

Publication type:

Article

Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 Prevention.

Published in:

Pharmaceutical Research, 2015, v. 32, n. 11, p. 3768, doi. 10.1007/s11095-015-1738-7

By:

Dezzutti, Charlene;
Yandura, Sarah;
Wang, Lin;
Moncla, Bernard;
Teeple, Elizabeth;
Devlin, Brid;
Nuttall, Jeremy;
Brown, Elizabeth;
Rohan, Lisa

Publication type:

Article

INTENSIFIED TREATMENT QUICKLY REDUCES LOW-LEVEL VIRAL SHEDDING IN SEMEN.

Published in:: HIV Australia, 2013, v. 11, n. 1, p. 50
Publication type:: Article

Adherence and Acceptability of a Multidrug Vaginal Ring for HIV Prevention in a Phase I Study in the United States.

Published in:

AIDS & Behavior, 2016, v. 20, n. 11, p. 2644, doi. 10.1007/s10461-016-1299-8

By:

Straten, Ariane;
Panther, Lori;
Laborde, Nicole;
Hoesley, Craig J.;
Cheng, Helen;
Husnik, Marla J.;
Horn, Stephanie;
Nel, Annalene;
Soto-Torres, Lydia;
Chen, Beatrice

Publication type:

Article

Maraviroc-Mediated Lung Protection following Trauma-Hemorrhagic Shock.

Published in:

BioMed Research International, 2016, v. 2016, p. 1, doi. 10.1155/2016/5302069

By:

Liu, Fu-Chao;
Zheng, Chih-Wen;
Yu, Huang-Ping

Publication type:

Article

In vitro replicative fitness of early Transmitted founder HIV-1 variants and sensitivity to Interferon alpha.

Published in:

Scientific Reports, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41598-020-59596-x

By:

Ashok kumar, Manickam;
Sonawane, Aanand;
Sperk, Maike;
Tripathy, Srikanth P.;
Neogi, Ujjwal;
Hanna, Luke Elizabeth

Publication type:

Article

Maraviroc Intensification Improves Endothelial Function in Abacavir-Treated Patients, an Open-Label Randomized Cross-Over Pilot Study.

Published in:

Infectious Diseases & Therapy, 2016, v. 5, n. 3, p. 389, doi. 10.1007/s40121-016-0115-0

By:

Krikke, Maaike;
Tesselaar, Kiki;
Arends, Joop;
Drylewicz, Julia;
Otto, Sigrid;
Lelyveld, Steven;
Visseren, Frank;
Hoepelman, Andy

Publication type:

Article

In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells.

Published in:

Clinical & Experimental Immunology, 2011, v. 166, n. 2, p. 184, doi. 10.1111/j.1365-2249.2011.04409.x

By:

Rossi, R.;
Lichtner, M.;
De Rosa, A.;
Sauzullo, I.;
Mengoni, F.;
Massetti, A. P.;
Mastroianni, C. M.;
Vullo, V.

Publication type:

Article

Successful treatment of progressive multifocal leukoencephalopathy with recombinant interleukin-7 and maraviroc in a patient with idiopathic CD4 lymphocytopenia.

Published in:

Journal of NeuroVirology, 2018, v. 24, n. 5, p. 652, doi. 10.1007/s13365-018-0657-x

By:

Harel, Asaff;
Horng, Sam;
Gustafson, Tarah;
Ramineni, Anil;
Farber, Rebecca Straus;
Fabian, Michelle

Publication type:

Article

Correction to: CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.

Published in:

2018

By:

Barber, T. J.;
Imaz, A.;
Boffito, M.;
Niubó, J.;
Pozniak, A.;
Fortuny, R.;
Alonso, J.;
Davies, N.;
Mandalia, S.;
Podzamczer, D.;
Gazzard, B.

Publication type:

Correction Notice

CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.

Published in:

Journal of NeuroVirology, 2018, v. 24, n. 1, p. 98, doi. 10.1007/s13365-017-0600-6

By:

Barber, T. J.;
Imaz, A.;
Boffito, M.;
Niubó, J.;
Pozniak, A.;
Fortuny, R.;
Alonso, J.;
Davies, N.;
Mandalia, S.;
Podzamczer, D.;
Gazzard, B.

Publication type:

Article

Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND)

Published in:

Journal of NeuroVirology, 2014, v. 20, n. 6, p. 571, doi. 10.1007/s13365-014-0279-x

By:

Ndhlovu, Lishomwa;
Umaki, Tracie;
Chew, Glen;
Chow, Dominic;
Agsalda, Melissa;
Kallianpur, Kalpana;
Paul, Robert;
Zhang, Guangxiang;
Ho, Erika;
Hanks, Nancy;
Nakamoto, Beau;
Shiramizu, Bruce;
Shikuma, Cecilia

Publication type:

Article